Is It Adverse, Nonadverse, Adaptive, or Artifact?

Author:

Pandiri Arun R.1,Kerlin Roy L.2,Mann Peter C.3,Everds Nancy E.4,Sharma Alok K.5,Myers L. Peyton6,Steinbach Thomas J.7

Affiliation:

1. National Toxicology Program, Research Triangle Park, North Carolina, USA

2. Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, USA

3. Experimental Pathology Laboratories, Inc., Northwest, Seattle, Washington, USA

4. Amgen Inc., South San Francisco, California, USA

5. Covance Laboratories, Madison, Wisconsin, USA

6. U.S. Food and Drug Administration, Silver Spring, Maryland, USA

7. Experimental Pathology Laboratories, Inc., Durham, North Carolina, USA

Abstract

One of the principal challenges facing a toxicologic pathologist is to determine and differentiate a true adverse effect from a nonadverse or an adaptive response. Recent publications from the Society of Toxicologic Pathology (STP) and the European STP provide guidance for determining and communicating adversity in nonclinical toxicology studies. In order to provide a forum to inform and engage in a discussion on this important topic, a continuing education (CE) course was held during the 2016 STP Annual meeting in San Diego, CA. The lectures at this course provided guidance on determining and communicating adversity using case studies involving both clinical pathology and anatomic pathology. In addition, one talk also focused on data quality, study design, and interpretation of artifacts that could hinder the determination of adversity. The CE course ended with a talk on understanding adversity in preclinical studies and engaging the regulatory agencies in the decision-making process. This manuscript is designed to provide brief summaries of all the talks in this well-received CE course.

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference27 articles.

1. LETTER TO THE EDITOR

2. Improved Method for Selection of the NOAEL

3. Cavagnaro J. A., Beilke L. D. (2014). What the AEL is the NOAEL? In American College of Toxicology. 35th Annual Meeting, Orlando, FL. http://www.actox.org/am/am2014/docs/ACT_AM14Program.pdf.

4. Center for Drug Evaluation and Research (CDER). (2005). Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, 40CFR Part 261. Washington, DC: U.S. Government Printing Office. http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf.

5. Differentiating Spontaneous from Drug-Induced Vascular Injury in the Dog

Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3